| Literature DB >> 28716138 |
R Akuffo1,2,3, G Armah4, M Clemens5,6, K C Kronmann7,8, A H Jones5,6, P Agbenohevi9, K Sagoe10, N Puplampu7, N Talla Nzussouo11, W Ampofo4, K Koram4, C Duplessis7, E Dueger5,6,11.
Abstract
BACKGROUND: Diarrhea is an important cause of morbidity and mortality worldwide. In Africa and Ghana in particular, it is estimated to contribute directly to 19 and 25% of pediatric mortality among children under 5 years, respectively.Entities:
Keywords: Diarrhea; Enteric; Hospitalized; Infections; Pathogens; Prevalence; Surveillance
Mesh:
Year: 2017 PMID: 28716138 PMCID: PMC5514524 DOI: 10.1186/s13104-017-2621-x
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Distribution of enrolled participants and samples received from study sites
| Study site | Enrolled, n (%) | Samples received, n (%) |
|---|---|---|
| TTH | 141 (32.9) | 44 (28.8) |
| 37MH | 288 (67.1) | 109 (71.2) |
| Total | 429 | 153 |
TTH Tamale Teaching Hospital, 37MH 37 Military Hospital
Demographic and clinical characteristics of enrolled ADI cases
| Characteristic | Subgroups | Enrolled (N = 429) |
|---|---|---|
| Age group | 31 days to <1 years | 98 (22.8) |
| 1 to <5 years | 118 (27.5) | |
| 5 to <18 years | 21 (4.9) | |
| 18 to <65 years | 171 (39.9) | |
| 65 years+ | 21 (4.9) | |
| Male | 200 (46.6) | |
| Sex | Female | 221 (51.5) |
| Missing | 8 (1.9) | |
| Antibiotic use prior to admission | 49 (11.4) | |
| Antibiotic use | Antibiotic use prior to sample collection | 338 (78.8) |
| Outcomea | Discharge | 395 (96.6) |
| Death | 12 (2.9%) | |
| Unknown/missing | 22 (5.4) |
Data is represented in N (%)
aOutcome data available for 409 participants
Duration of diarrheal symptoms among enrolled study participants (N = 429); Nov 2010–Sep 2012
| Duration of diarrheal symptoms (days) | Number of participants |
|---|---|
| 0–1 | 98 (22.8) |
| 2–3 | 185 (43.2) |
| 4–5 | 104 (24.2) |
| 6–7 | 35 (8.2) |
| 8–9 | 3 (0.7) |
| 10–12 | 4 (0.9) |
Data is represented in N (%)
Antimicrobial susceptibility testing results for Salmonella sp. and Plesiomonas sp.
| Antimicrobial agent | Disk conten (μg) | Inhibition zone diameter for different pathogens (mm)b | |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Amikacin | 30 | 18 | 17 | 12a | 12a |
| Ampicillin | 10 | 8a | 9a | 8a | 8a |
| Ampicillin–sulbactam | 10/10 | 18 | 18 | 17 | 19 |
| Aztreonam | 30 | 14a | 12a | 13a | 14a |
| Cefotaxime | 30 | 28 | 27 | 30 | 29 |
| Cephalothin | 30 | 20 | 21 | 11a | 12a |
| Chloramphenicol | 30 | 9a | 9a | 15 | 16 |
| Ciprofloxacin | 5 | 12a | 11a | 24 | 23 |
| Gentamycin | 10 | 14 | 13 | 8a | 8a |
| Imipenem | 10 | 26 | 24 | 17a | 15a |
| Nalidixic acid | 30 | 10a | 9a | 9a | 8a |
| Tetracycline | 30 | 8a | 8a | 10a | 9a |
| Trimethoprim/sulfamethoxazole | 23.75 | 18 | 19 | 8a | 8a |
aResistant
bCut-off inhibition zone diameter values determined using the performance standards for antimicrobial susceptibility testing twenty-first informational supplement for CLSI [12]
Fig. 1Monthly distribution of ADI enrolled cases (lower panel, n = 429) and pathogens detected from samples tested (upper panel, n = 83); Nov 2010–Oct 2012
Age distribution of stool pathogens detected (N = 83); Nov 2010–Sep 2012
| Stool pathogens | Frequency | Age groupa | ||
|---|---|---|---|---|
| 31 days to <1 years | 1–5 years | >5 years | ||
| Rotavirus | 41 | 17 (41.5) | 22 (53.7) | 2 (4.9) |
| Norovirus | 10 | 3 (30.0) | 2 (20.0) | 5 (50.0) |
| Astrovirus | 11 | 4 (36.4) | 2 (18.2) | 5 (45.5) |
| Adenovirus | 8 | 4 (50.0) | 3 (37.5) | 1 (12.5) |
|
| 4 | 3 (75.0) | 0 (0) | 1 (25.0) |
|
| 3 | 2 (66.7) | 0 (0) | 1 (33.3) |
|
| 2 | 1 (50.0) | 1 (50.0) | 0 (0) |
|
| 2 | 2 (100.0) | 0 (0) | 0 (0) |
|
| 1 | 0 (0) | 0 (0) | 1 (100.0) |
|
| 1 | 1 (100.0) | 0 (0) | 0 (0) |
| Total | 83 | 37 (44.6) | 30 (36.1) | 16 (19.3) |
aData is represented in N (%)